Guiducci S et al. – No detectable differences were observed between patients treated with quinapril and those receiving placebo. Although no severe adverse effects were observed, patients taking quinapril experienced significantly more adverse effects. Methods
Study to evaluate the efficacy of the ACE inhibitor quinapril for the management of vascular damage in systemic sclerosis (SSc)
213 pts with limited cutaneous SSc or Raynaud's phenomenon (mean age 54 yrs, 182 females) were randomly assigned to receive 80 mg/day, or the maximum tolerated dose, of quinapril (n=105) or placebo (n=108) for 2–3 yrs
Pts were assessed every 3 mos
Results
The number of new ischemic digital ulcers was recorded as the primary end point
Frequency of Raynaud's phenomenon episodes, skin score, health status, pulmonary artery pressure and treatments for ischemia were monitored as secondary end points
There were no detectable differences between pts treated with quinapril and those receiving placebo
No severe adverse effects were observed
Pts taking quinapril experienced significantly more adverse effects
